Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Neuropeptide Systems and Schizophrenia

Author(s): Amber L. LaCrosse and M. Foster Olive

Volume 12, Issue 5, 2013

Page: [619 - 632] Pages: 14

DOI: 10.2174/1871527311312050010

Price: $65

Abstract

Schizophrenia affects approximately 1% of the world population, and the majority of pharmacologically based treatments for this disorder are ligands that interact with monoaminergic transmission. However, there is a wealth of evidence that various neuropeptides are often co-released with monoamine neurotransmitters, and that ligands acting at neuropeptide receptors modulate monoaminergic transmission as well as schizophrenia-related behaviors in preclinical animal models. Such neuropeptide systems include neurotensin, cholecystokinin, corticotropin releasing factor, neuropeptide Y, oxytocin, opioid peptides, tachykinins, thyrotropin-releasing hormone, and orexins. The purpose of this review will be to summarize the existing preclinical and clinical literature on the role of various neuropeptide systems as modulators of schizophrenia-related behaviors, and the potential of targeting these systems for the development of novel antipsychotic medications.

Keywords: Schizophrenia, antipsychotic, dopamine, neuropeptide, positive symptoms, negative symptoms, cognitive deficits.


Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy